Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 283

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 283
---
 of Mr.Olivier Samuel, Mr.Eran Iohan and Ms. Liora Oren. At the extraordinary shareholders’ meeting, shareholders of the Company will be asked to elect Olivier Samuel, Eran Iohan and Liora Oren as members of the Compensation, Nomination and Governance Committee for a term lasting until the next annual ordinary shareholders’ meeting. To approve this Proposal10, a resolution passed by a Simple Majority Vote is required. You may vote “FOR,” “AGAINST” or “ABSTAIN” on Proposal 10. A failure to vote, an abstention or a broker non -vote, if any, will have the same effect as a vote “AGAINST” Proposal 10. THE NLS BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE
“FOR” PROPOSAL 10. 120 Advisory vote: Approval of Composition of the new Senior Management following the Merger (PROPOSAL 11) According to Section 6.2.8 of the Merger Agreement, the current officers of the Company are required to resign from their positions (other than Eric Konofal who shall remain in part -timepositions) prior to the effectiveness of the Merger and the Company is required to appoint the executive officers of Kadimastem as executive officers of the Company upon the effective time of the Merger. Accordingly, at the extraordinary shareholders’ meeting, shareholders of the Company will be asked, on an advisory basis, to approve Mr. Ronen Twito as Chairman and Chief Executive Officer, Prof. Michel Revel, MD, PhD, as Chief Scientific Officer, Mr. Kfir Molakandov, PhD, as Vice President Research and Development, Mr. Ariel Revel, MD, as Director of Medical Affairs and Dr. Eric Konofal, MD, Ph.D. as Head of DOXA program. NLS is holding a shareholder advisory vote on the appointment of new executive officers. A resolution resulting from such an advisory vote lacks legal binding effect under Swiss law. Therefore, the NLS Board retains full decision -makingauthority and may proceed with a transaction even if shareholders vote against Proposal 11. The NLS Board shall nonetheless consider the shareholders’ vote on Proposal 11 in its decision -makingprocess. Biographical information concerning Mr. Ronen Twito, Prof. Michel Revel, Mr. Kfir Molakandov and Mr. Ariel Revel is set forth below: Ronen Twito CPA, Executive Chairman & Chief Executive Officer Mr.Ronen Twito